Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

Sixteen (16) diabetic subject with endothelial dysfunction will be scheduled to undergo a
peripheral intravenous infusion after meeting all inclusion/exclusion criteria at baseline.

Eight (8) subjects will be treated with 20 million (2 x 10^7) allogeneic hMSC's and eight (8)
subjects will be treated with 100 million (100 x 10^6) allogeneic hMSC's

Follow up: Subjects will be followed at 3, 7, 14, 28 days, and 3 month post-infusion to
complete all safety and efficacy assessments and at 6 and 12 months post-infusion to complete
safety assessments.

Inclusion Criteria:

- Be ≥ 21 and < 90 (inclusive) years of age.

- Provide written informed consent.

- Have endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD <7%).

- Have an ejection fraction > 45% by gated blood pool scan, two- dimensional
echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3
months.

- Have Diabetes mellitus type 2 documented by hemoglobin adult type 1 component (A1C) >
7% or on medical therapy for diabetes.

- Females of childbearing potential must use two forms of birth control for the duration
of the study. Female subjects must undergo a blood or urine pregnancy test at
screening and within 36 hours prior to infusion.

Exclusion Criteria:

In order to participate in this study, a subject Must Not:

- Be younger than 21 years or older than 90 years of age.

- Have a baseline glomerular filtration rate <35 ml/min 1.73m^2 estimated using the
Modification of Diet in renal disease (MDRD) formula.

- Have poorly controlled blood glucose levels with hemoglobin A1C > 8.5%.

- Have a history of proliferative retinopathy or severe neuropathy requiring medical
treatment.

- Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell <
2,500/ul or platelet values < 100,000/ul without another explanation.

- Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times
the upper limit of normal.

- Have a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from
anticoagulation therapy, or will refuse blood transfusions.

- Have Lymphadenectomy or Lymph node dissection in the right arm.

- Be an organ transplant recipient or have a history of organ or cell transplant
rejection.

- Have a clinical history of malignancy within the past 5 years (i.e., subjects with
prior malignancy must be disease free for 5 years), except curatively- treated basal
cell or squamous cell carcinoma, or cervical carcinoma.

- Have a condition that limits lifespan to < 1 year.

- Have a history of drug or alcohol abuse within the past 24 months.

- Be on chronic therapy with immunosuppressant medication, such as corticosteroids or
Tumor Necrosis Factor - alpha (TNFα) antagonists.

- Be serum positive for HIV, Syphilis - VDRL (Confirmation with FTA-ABS if needed
(Syphilis)), hepatitis B surface antigen or viremic hepatitis C.

- Be currently participating (or participated within the previous 30 days) in an
investigational therapeutic or device trial.

- Be pregnant, nursing, or of childbearing potential while not practicing effective
contraceptive methods.

- Any other condition that in the judgment of the Investigator would be a
contraindication to enrollment or follow-up.